Company Encyclopedia
View More
name
OptimizeRx
OPRX.US
OptimizeRx Corporation operates as a digital healthcare technology company. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awareness, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. It also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is based in Waltham, Massachusetts.
70.40 B
OPRX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care TechnologyIndustry
Industry Ranking6/44
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.03%D
    • Profit Margin0.03%D
    • Gross Margin67.20%A
  • Growth ScoreB
    • Revenue YoY24.18%A
    • Net Profit YoY100.14%A
    • Total Assets YoY3.10%C
    • Net Assets YoY6.81%B
  • Cash ScoreA
    • Cash Flow Margin322076.47%A
    • OCF YoY24.18%A
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreB
    • Gearing Ratio28.22%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    OptimizeRx Unveils Presentation Showcasing Technology Solutions for Patient Engagement and Pharma Connectivity

    OptimizeRx Corporation has unveiled a new corporate presentation highlighting its technology solutions for enhancing patient engagement and connectivity with life sciences organizations. The presentation details their AI-driven platform and nationwide network connecting U.S. physicians and patients. Key financials include a market cap of $301 million, share price of $16.15, and cash reserves of $19.5 million. The company is listed on NASDAQ under OPRX. This announcement was made on November 18, 2025, by OptimizeRx.

    Reuters·
    US
    OPRX
    +2.30%
    Reuters·
    US
    OPRX
    +2.30%

    OptimizeRx (NASDAQ:OPRX) Issues Earnings Results, Beats Expectations By $0.17 EPS

    OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 EPS, exceeding expectations by $0.17. Revenue reached $26.07 million, surpassing estimates of $23.83 million. The company has a positive return on equity of 4.50% and a negative net margin of 9.42%. Following the earnings report, OPRX stock fell to $15.65. Insider transactions included CEO Stephen L. Silvestro selling shares, and institutional investors increased their stakes. Analysts have mixed ratings, with a consensus target price of $14.45 and a majority rating of "Moderate Buy."

    Market Beat·
    US
    OPRX
    +2.30%
    Market Beat·
    US
    OPRX
    +2.30%

    OptimizeRx Earnings Call: Strong Q3 and Upbeat Outlook

    OptimizeRx Corporation reported strong Q3 earnings with a 22% revenue increase to $26.1 million and adjusted EBITDA rising to $5.1 million. The company raised its guidance for 2025 and 2026, projecting revenues of $105-$109 million and $118-$124 million respectively. Despite a conservative outlook for Q4 due to increased operating expenses, the overall sentiment remains positive, focusing on operational excellence and debt reduction. The gross margin improved to 67.2%, and favorable RFP trends indicate strong growth potential. OptimizeRx is committed to sustaining growth and financial stability.

    Tip Ranks·
    US
    OPRX
    +2.30%
    Tip Ranks·
    US
    OPRX
    +2.30%

    OptimizeRx | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 26.07 M

    LB filings·
    US
    OPRX
    +2.30%
    LB filings·
    US
    OPRX
    +2.30%

    OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating

    William Blair analyst Ryan Daniels has maintained a Buy rating on OptimizeRx (OPRX) stock, citing strong financial performance and a promising outlook. The company reported impressive Q3 2025 results, with revenue and adjusted EBITDA exceeding expectations, driven by increased digital marketing spend from pharmaceutical clients. Management raised future revenue and EBITDA guidance, indicating continued growth into 2026. The focus on recurring revenue and data services is expected to enhance margins. Lake Street also maintained a Buy rating with a $20.00 price target.

    Tip Ranks·
    US
    OPRX
    +2.30%
    Tip Ranks·
    US
    OPRX
    +2.30%
    © 2025 Longbridge｜Disclaimer